People and Business News — 4/22
People News
COTA, Inc. appointed Miruna Sasu, PhD as president and chief executive
officer.
AiCure has hired Andre Paredes, PhD, as Director of OpenDBM Community, Sarah Kark, PhD, as Senior Digital Neuroscientist, and Sondra Pepe, as VP of Product Operations.
CluePoints has appointed Catherine Ditzler as VP Marketing while Céline Daubresse joins as VP People, and James Faust as the new VP Business Operations.
Suvoda expanded its leadership team with the additions of Andrew McVeigh as Chief Architect and Steve DeSantisas Chief Financial Officer.
Qlucore appointed Erik Söderbäck as head of diagnostics sales.
BioIVT announced the appointment of Jennifer Murphy as Senior Vice President of Global Commercial Operations.
Business News
Daelight Solutions renewed its Preferred certification status for Implementation Support and Business Process/Strategy services for Veeva’s Vault eTMF.
ActiGraph joined the Decentralized Trials & Research Alliance.
Medidata announced Labcorp has selected their technology platform to extend their 14-year partnership.
AiCure opened its first international office in Nanjing, China.
Recognition
Proxima Clinical Research was named to the Inc. Regionals 2022 Southwest list of the Fastest-Growing Private Companies; and was recognized by the Houston Business Journal as a company to watch, as noted in its inaugural Houston Inno Fire Awards.
Thermo Fisher Scientific won a 2021 TOPRA Award for Regulatory Excellence.
CluePoints won the Citeline Award for Excellence in Innovation in Response to COVID-19 – Clinical Trial Activities.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
